GlassScriptPhysician profile
Grant Kohler Mathews
NPI 1689898843
$2,077.81
in general payments reported to CMS, 2019-2025
20 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $241 · 2021: $286 · 2022: $104 · 2023: $197 · 2024: $366 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023 · Education: $11.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.33 |
| Education | $11.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $303.46 | 2019-2025 | |
| Travere Therapeutics, INC. | $266.37 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $236.47 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.03 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $148.03 | 2019-2025 | Farxiga |
| Mauna Kea Technologies, INC. | $126.67 | 2021-2023 | |
| Vifor Pharma, INC. | $115.50 | 2019-2024 | Veltassa |
| Horizon Therapeutics Plc | $114.31 | 2020-2022 | |
| Mylan Specialty L.P. | $73.74 | 2019 | |
| Mallinckrodt Hospital Products INC. | $70.55 | 2020 | |
| Novo Nordisk INC | $63.19 | 2023-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Amgen INC. | $60.68 | 2023 | Tavneos |
| Baxter Healthcare | $57.72 | 2020-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Mallinckrodt Enterprises LLC | $51.59 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38.13 | 2025 | Cds - Mct/Cem Monitoring |
| Regeneron Healthcare Solutions, INC. | $24.24 | 2020 | |
| Alnylam Pharmaceuticals INC. | $23.37 | 2024 | Givlaari |
| Akebia Therapeutics INC | $19.92 | 2019 | |
| Grifols USA, LLC | $16.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.